{"id":19795,"date":"2021-06-29T18:39:45","date_gmt":"2021-06-29T16:39:45","guid":{"rendered":"https:\/\/www.hollandbio.nl\/?p=19795"},"modified":"2021-06-29T18:39:46","modified_gmt":"2021-06-29T16:39:46","slug":"immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/","title":{"rendered":"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Immunicum AB (publ) announced<\/strong> <strong>that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company\u2019s lead cancer relapse vaccine candidate, in High-Grade Serous Ovarian Cancer (HGSOC) patients following primary standard of care treatment.<\/strong> <strong>The ALISON study is carried out by Professor Hans Nijman and his research group in Groningen, the Netherlands, and investigates the ability of DCP-001 to trigger the immune system to control cancer cells that may have remained in the body after surgery and treatment with chemotherapy in order to prevent or reduce tumor reccurence.<\/strong> <strong>This is the first study using Immunicum\u2019s cancer relapse vaccine approach to target a solid tumor indication and will evaluate the safety, feasibility and immunogenicity of DCP-001.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThe start of the Phase I ALISON study with the first patient enrolled marks an important milestone in our clinical development strategy, as ovarian cancer is a completely new indication for Immunicum and the study is the first evaluation of DCP-001 in a solid tumor indication,\u201d <strong>commented Jeroen Rovers, Chief Medical Officer at Immunicum<\/strong>. \u201cOther immunotherapies such as checkpoint inhibitors have shown relatively low responses in ovarian cancer. This study builds on our promising preclinical data showing significant reduction in tumor growth following DCP-001 administration and will further evaluate the immunogenicity of our cancer relapse vaccine candidate in patients with solid tumors for the first time.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hans W Nijman, MD, PhD, Principal Investigator of the ALISON <\/strong><strong>study<\/strong><strong> and Professor at University Medical <\/strong><strong>Center <\/strong><strong>in Groningen, <\/strong><strong>the <\/strong><strong>Netherlands, added:<\/strong> \u201cTumors tend to develop ways that allow them to evade the body\u2019s immune response against them, hence making the tumors resistant to many therapies. Immunicum\u2019s relapse vaccine candidate contains allogeneic dendritic cells that can boost various key elements of the immune system against multiple tumor antigens, potentially making it a vital component in the fight against tumor recurrence and clinical relapse in ovarian cancer patients.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase I ALISON study is a single-center, open-label study evaluating safety and efficacy of DCP-001 in High-Grade Serous Ovarian Cancer (HGSOC) patients. HGSOC is a unique type of epithelial cancer that is characterized by the loss of function of the tumor suppressor protein, p53, which can lead to chemotherapy resistance and disease relapse. The vaccination regimen with DCP-001 will be scheduled after standard of care treatment, which includes chemotherapy either before or after debulking surgery, and will start 6 weeks following the last cycle of chemotherapy. Patients will receive 4 bi-weekly vaccinations with 25 million cells per DCP-001 vaccination and 2 additional booster vaccinations with 10 million cells per vaccination. Patient follow-ups will be conducted for 24 months. The primary endpoint of the study is change from baseline of DCP-001 vaccine antigen-specific T cells in peripheral blood after treatment. Key secondary endpoints include safety and tolerability after repeated DCP-001 dosing as well as recurrence free survival (RFS) and overall survival (OS) during the follow-up period.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Source: Immunicum (<a href=\"https:\/\/www.globenewswire.com\/news-release\/2021\/06\/23\/2251450\/0\/en\/Immunicum-Announces-Enrollment-of-First-Patient-in-Phase-I-ALISON-Study-Evaluating-Cancer-Relapse-Vaccine-Candidate-DCP-001-in-Ovarian-Cancer.html\">Press release<\/a>)<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Immunicum AB (publ) announced that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company\u2019s lead cancer relapse vaccine candidate, in High-Grade Serous Ovarian Cancer (HGSOC) patients following primary standard of care treatment. The ALISON study is carried out by Professor Hans Nijman and his research group in [&hellip;]<\/p>\n","protected":false},"author":16,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-19795","post","type-post","status-publish","format-standard","hentry","category-gezondheid"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - hollandbio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - hollandbio\" \/>\n<meta property=\"og:description\" content=\"Immunicum AB (publ) announced that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company\u2019s lead cancer relapse vaccine candidate, in High-Grade Serous Ovarian Cancer (HGSOC) patients following primary standard of care treatment. The ALISON study is carried out by Professor Hans Nijman and his research group in [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"hollandbio\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-29T16:39:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-06-29T16:39:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"HollandBIO\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:site\" content=\"@hollandbio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"HollandBIO\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\\\/\"},\"author\":{\"name\":\"HollandBIO\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\"},\"headline\":\"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer\",\"datePublished\":\"2021-06-29T16:39:45+00:00\",\"dateModified\":\"2021-06-29T16:39:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\\\/\"},\"wordCount\":502,\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"articleSection\":[\"Gezondheid\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\\\/\",\"name\":\"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - hollandbio\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\"},\"datePublished\":\"2021-06-29T16:39:45+00:00\",\"dateModified\":\"2021-06-29T16:39:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/nieuws\\\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"name\":\"hollandbio\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#organization\",\"name\":\"hollandbio\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.hollandbio.nl\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/HollandBIO_logo.svg\",\"width\":218.664,\"height\":29.659,\"caption\":\"hollandbio\"},\"image\":{\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/hollandbio\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hollandbio\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.hollandbio.nl\\\/en\\\/#\\\/schema\\\/person\\\/48824449f08e494bb7ea02e1ff5dd6ea\",\"name\":\"HollandBIO\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - hollandbio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/","og_locale":"en_US","og_type":"article","og_title":"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - hollandbio","og_description":"Immunicum AB (publ) announced that the first patient has been enrolled in the Phase I ALISON clinical study evaluating DCP-001, the Company\u2019s lead cancer relapse vaccine candidate, in High-Grade Serous Ovarian Cancer (HGSOC) patients following primary standard of care treatment. The ALISON study is carried out by Professor Hans Nijman and his research group in [&hellip;]","og_url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/","og_site_name":"hollandbio","article_published_time":"2021-06-29T16:39:45+00:00","article_modified_time":"2021-06-29T16:39:46+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2025\/01\/hb-opengraph_illu.png","type":"image\/png"}],"author":"HollandBIO","twitter_card":"summary_large_image","twitter_creator":"@hollandbio","twitter_site":"@hollandbio","twitter_misc":{"Written by":"HollandBIO","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/#article","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/"},"author":{"name":"HollandBIO","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea"},"headline":"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer","datePublished":"2021-06-29T16:39:45+00:00","dateModified":"2021-06-29T16:39:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/"},"wordCount":502,"publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"articleSection":["Gezondheid"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/","url":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/","name":"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer - hollandbio","isPartOf":{"@id":"https:\/\/www.hollandbio.nl\/en\/#website"},"datePublished":"2021-06-29T16:39:45+00:00","dateModified":"2021-06-29T16:39:46+00:00","breadcrumb":{"@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.hollandbio.nl\/en\/nieuws\/immunicum-announces-enrollment-of-first-patient-in-phase-i-alison-study-evaluating-cancer-relapse-vaccine-candidate-dcp-001-in-ovarian-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.hollandbio.nl\/en\/"},{"@type":"ListItem","position":2,"name":"Immunicum Announces Enrollment of First Patient in Phase I ALISON Study Evaluating Cancer Relapse Vaccine Candidate DCP-001 in Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/www.hollandbio.nl\/en\/#website","url":"https:\/\/www.hollandbio.nl\/en\/","name":"hollandbio","description":"","publisher":{"@id":"https:\/\/www.hollandbio.nl\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.hollandbio.nl\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.hollandbio.nl\/en\/#organization","name":"hollandbio","url":"https:\/\/www.hollandbio.nl\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","contentUrl":"https:\/\/www.hollandbio.nl\/wp-content\/uploads\/2023\/08\/HollandBIO_logo.svg","width":218.664,"height":29.659,"caption":"hollandbio"},"image":{"@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/hollandbio","https:\/\/www.linkedin.com\/company\/hollandbio\/"]},{"@type":"Person","@id":"https:\/\/www.hollandbio.nl\/en\/#\/schema\/person\/48824449f08e494bb7ea02e1ff5dd6ea","name":"HollandBIO"}]}},"_links":{"self":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/19795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/comments?post=19795"}],"version-history":[{"count":0,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/posts\/19795\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/media?parent=19795"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/categories?post=19795"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hollandbio.nl\/en\/wp-json\/wp\/v2\/tags?post=19795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}